Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

ClinicalTrials.gov ID: NCT04079179

Public ClinicalTrials.gov record NCT04079179. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study to Assess the Safety and Efficacy of Cobimetinib in Refractory Langerhans Cell Histiocytosis, LCH-Associated Neurodegenerative Disease, and Other Histiocytic Disorders.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a research study of a drug called cobimetinib in children and adults diagnosed with Langerhans cell histiocytosis (LCH), and other histiocytic disorders that has returned or does not respond to treatment. Cobimetinib blocks activation of a protein called Mitogen-activated protein kinase (MEK) that is part of incorrect growth signals in histiocytosis cells. Four different groups of patients will be enrolled.

Study identification

NCT ID: NCT04079179
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2
Lead sponsor: Carl Allen; Other
Enrollment: 90 participants

Conditions and interventions

Conditions

Interventions

Cobimetinib Drug

Drug

Eligibility (public fields only)

Age range: Not listed
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Apr 19, 2021 (Actual)
Primary completion: Jan 2028 (Estimated)
Completion: Dec 2029 (Estimated)
Last update posted: Oct 26, 2026

2021 – 2029

United States locations

U.S. sites: 12
U.S. states: 10
U.S. cities: 12

Facility	City	State	ZIP	Site status
Phoenix Children's Hospital	Phoenix	Arizona	85016	Recruiting
Arkansas Children's Hospital	Little Rock	Arkansas	72202	Recruiting
Children's Hospital of Orange County	Orange	California	92868	Recruiting
UCSF Benioff Children's Hospital	San Francisco	California	94158	Recruiting
Children's National Hospital	Washington D.C.	District of Columbia	20010	Recruiting
John Hopkins University School of Medicine	Baltimore	Maryland	21287	Recruiting
Dana Farber Cancer Institute, Boston Children's	Boston	Massachusetts	02215	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
NACHO Consortium	Memphis	Tennessee	38105	Not yet recruiting
Children's Medical Center- UTSW	Dallas	Texas	75235	Recruiting
Texas Children's Hospital	Houston	Texas	77030	Recruiting
University of Wisconsin-American Family Children's Hospital	Madison	Wisconsin	53792	Terminated

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04079179, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 26, 2026 · Synced Oct 27, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT04079179 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →